The National Institute for Health and Care Excellence (NICE) has opted against recommending Crysvita (burosumab) to treat adults in England and Wales who have a confirmed diagnosis of X-linked hypophosphataemia (XLH).
Drug developer Kyowa Kirin (TYO: 4151) has expressed disappointment at NICE’s decision, outlined in its initial Appraisal Consultation Document (ACD), but said that the company remains committed to finding a solution for adults living with XLH to have access to the medicine, and vowed to continue working with the NICE, NHS England and others to find a resolution.
"We fully support the UK Rare Disease Framework and specifically priority four - improving access to specialist care, treatments and drugs"Kyowa Kirin warned that the decision would create a disparity in access between England and Wales on the one hand, and Scotland on the other.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze